Portal de Periódicos da CAPES

A drug of the past, a lesson for the future

2005; Wiley; Volume: 9; Issue: 3 Linguagem: Inglês

10.1111/j.1399-3046.2005.00332.x

1399-3046

Flavio Vincenti,

Monoclonal and Polyclonal Antibodies Research

Pediatric TransplantationVolume 9, Issue 3 p. 267-268 A drug of the past, a lesson for the future Flavio Vincenti MD, Flavio Vincenti MD University of California at San Francisco San Francisco, CA 94143, USA E-mail: [email protected]Search for more papers by this author Flavio Vincenti MD, Flavio Vincenti MD University of California at San Francisco San Francisco, CA 94143, USA E-mail: [email protected]Search for more papers by this author First published: 17 May 2005 https://doi.org/10.1111/j.1399-3046.2005.00332.xCitations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985: 313: 337–342. 2 Port FK, Dykstra DM, Merion RM, Wolfe RA. Organ donation and transplant trends in the USA, 2003. Am J Transplant 2004: 4 (Suppl. 9): 7–12. 3 Abramowicz D, Goldman M, De Pauw L, Vanher Weghem JL, Kinnaert P, Vereerstraeten P. The long term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation: a single-center, prospective, randomized study. Transplantation 1992: 54: 433–437. 4 Norman DJ, Kahana L, Stuart FP Jr, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993: 55: 44–50. 5 Spanish Monotherapy Study Group. Cyclosporine therapy versus OKT3 and cyclosporine versus prednisone and cyclosporine as induction therapy in older renal transplant patients: a multicenter randomized study. Transplant Proc 1994: 26: 2522–2524. 6 Szczech LA, Berlin JA, Feldman HI. for the Anti-lymphocyte Antibody Induction Therapy Group. The effect of antilymphocyte induction therapy on renal allograft survival: a meta-analysis of individual patient-level data. Ann Intern Med 1998: 128: 817–826. 7 Shield CF, Edwards EB, Davies DB, Daily OP. Antilymphocyte induction therapy in cadaver renal transplantation: a retrospective, multicenter United Network for Organ Sharing study. Transplantation 1995: 63: 1257–1263. 8 Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. Transplantation 1995: 60: 1220–1224. 9 Hanto DW, Jendrisak MD, So SK, et al. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. Transplant Proc 1990: 22: 1755–1758. 10 McDonald R, Donaldson L, Emmett L, Tejani A. A decade of living donor transplantation in American children: the 1998 annual report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 2000: 4: 221–234. 11 Elshihabi I, Chavers B, Donaldson L, Emmett L, Tejani A. Continuing improvement in cadaver donor graft survival in North American children: the 1998 annual report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 2000: 4: 235–246. 12 Benfield MR, et al. A randomized multicenter trial of OKT3 mAbs induction compared to intravenous cyclosporine in pediatric renal transplantation. Pediatr Transplant in press. Citing Literature Volume9, Issue3June 2005Pages 267-268 ReferencesRelatedInformation